Journal of Neuro-Oncology

, Volume 61, Issue 3, pp 203–207 | Cite as

Plasma and Cerebrospinal Fluid Pharmacokinetics of Intravenous Temozolomide in Non-human Primates

  • Mahendra Patel
  • Cynthia McCully
  • Karen Godwin
  • Frank M. Balis


Temozolomide is a prodrug that undergoes spontaneous chemical degradation at physiologic pH to form the highly reactive alkylating agent, methyl-triazenyl imidazole carboxamide (MTIC). In clinical trials, temozolomide has activity in gliomas and is approved for recurrent anaplastic astrocytoma. We, therefore, studied the penetration of temozolomide into the cerebrospinal fluid (CSF) as a surrogate for blood–brain barrier penetration in a non-human primate model. Three Rhesus monkeys with indwelling Ommaya reservoirs received 7.5mg/kg (150mg/m2) of temozolomide as a 1h intravenous infusion. Frequent blood and CSF samples were obtained over 24h, plasma was immediately separated by centrifugation at 4°C, and plasma and CSF samples were acidified with HCl. Temozolomide concentration in plasma and CSF was measured by reverse-phase high-pressure liquid chromatography. Plasma temozolomide concentration peaked 0.5h after the end of the infusion and was 104±3μM. The mean peak CSF temozolomide concentration was 26±4μM at 2.5h. The mean areas under the temozolomide concentration–time curves in plasma and CSF were 392±18 and 126±18μMh, respectively, and the CSF:plasma ratio was 0.33±0.06. Clearance of temozolomide was 0.116±0.004l/kg/h, and the volume of distribution at steady state was 0.254±0.033l/kg. In this non-human primate model, temozolomide penetrated readily across the blood–brain barrier. These findings are consistent with the activity of temozolomide in brain tumors.

temozolomide pharmacokinetics cerebrospinal fluid blood–brain barrier brain tumors 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Friedman HS, Kerby T, Calvert H: Temozolomide and treatment of malignant glioma. Clin Cancer Res 6: 2585–2597, 2000Google Scholar
  2. 2.
    Stupp R, Gander M, Leyvraz S, Newlands E: Current and future developments in the use of temozolomide for the treatment of brain tumors. Lancet Oncol 2: 552–560, 2001Google Scholar
  3. 3.
    Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Branda M, Friedman HS, Albright R, Olson J, Chang SM, O'Neill AM, Friedman Ah, Bruner J, Yue N, Dugan M, Zaknoen S, Levin VA: Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytome at first relapse. Temodal Brain Tumor Group. J Clin Oncol 17: 2762–2771, 1999Google Scholar
  4. 4.
    Stevens MFG, Hickman JA, Langdon SP, Chubb D, Vickers L, Stone R, Baig G, Goddard C, Gibson NW, Stack JA, Newton C, Lunt E, Fizames C, Lavelle F: Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 47: 5846–5852, 1987Google Scholar
  5. 5.
    Gibson NW, Hickman JA, Erickson LD: DNA crosslinking and cytotoxicity in normal and transferred human cells treated in vitro with 8-carbamoyl-3-(2-chloroethyl)-imidazo [5-1-d], 1,2,3,5-tetrazin-4(3H)-one. Cancer Res 44: 1772–1775, 1985Google Scholar
  6. 6.
    Newlands ES: Current development of temozolomide (Abstract). Ann Oncol 5(Suppl 5): A197, 1994Google Scholar
  7. 7.
    Newlands ES, Blackledge GR, Slack JA, Rustin GJ, Smith DB, Stuart NS, Quarterman CP, Hoffman R, Stevens MF, Brampton MH, Gibson AC: Phase I trial of temozolomide (CCRG 81045: M & B 39831: NSC 362856). Br J Cancer 65: 287–291, 1992Google Scholar
  8. 8.
    Brada M, Judson I, Beale P, Moore S, Reidenberg P, Statkevich P, Dugan M, Batra V, Cutler D: Phase I doseescalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. Br J Cancer 81: 1022–1030, 1999Google Scholar
  9. 9.
    Hammond LA, Eckardt JR, Baker SD, Eckhardt SG, Dugan M, Forral K, Reidenberg P, Statkevich P, Weiss GR, Rinaldi DA, Von Hoff DD, Rowinsky EK: Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies. J Clin Oncol 17: 2604–2613, 1999Google Scholar
  10. 10.
    Nicholson HS, Ames MM, Krailo M, Reid JM, Seibel NL, Reaman GH: Phase I and pharmacokinetic study of temozolomide (TEM) in children and adolescents. A report from the children's cancer group (CCG) (Abstract). Proc Annu Meet Am Soc Clin Oncol 14: A1439, 1995Google Scholar
  11. 11.
    Reid JM, Stevens DC, Rubin J, Ames MM: Pharmacokinetics of 3-methyl-(triazen-1-yl)imidazole-4-carboximide following administration of temozolomide to patients with advanced cancer. Clin Cancer Res 3: 2393–2398, 1997Google Scholar
  12. 12.
    McCully CL, Balis FM, Bacher J, Phillips J, Poplack DG: A Rhesus monkey model for continuous infusion of drugs into cerebrospinal fluid. Lab Anim Sci 40: 520–525, 1990Google Scholar
  13. 13.
    Kim H, Likhari P, Parker D, Statkevich P, Marco A, Lin C-C, Nomeir AA: High-performance liquid chromatographic analysis and stability of anti-tumor agent temozolomide in human plasma. J Pharm Bio Anal 24: 461–468, 2001Google Scholar
  14. 14.
    Knott GD: MLAB – a mathematical modeling tool. Comput Programs Biomed 10: 261–280, 1979Google Scholar
  15. 15.
    O'Reilly SM, Newlands ES, Stevens MF, Smith DB, Brampton MH, Slack JA, Rustin GJ: Temozolomide has activity against primary brain tumors, melanoma and mycosis fungoides (Meeting abstract). Br J Cancer 65: 13, 1992Google Scholar
  16. 16.
    Baer JC, Freeman AA, Newlands ES, Watson AJ, Rafferty JA, Margison GP: Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells. Br J Cancer 67: 1299–1302, 1993Google Scholar
  17. 17.
    Stupp R, Osterman S, Leyvraz S, Csajka C, Buclin T, Decosterd LA: Cerebrospinal fluid levels of temozolomide as a surrogate marker for brain penetration (Abstract). Proc Am Soc Clin Oncol 20: 59a, 2001Google Scholar

Copyright information

© Kluwer Academic Publishers 2003

Authors and Affiliations

  • Mahendra Patel
    • 1
  • Cynthia McCully
    • 1
  • Karen Godwin
    • 1
  • Frank M. Balis
    • 1
  1. 1.Pediatric Oncology BranchNational Cancer InstituteBethesdaUSA

Personalised recommendations